CRIS · XBRL financial data

Curis financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CRIS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	11	11	10	10	11	9
General and administrative	12	17	20	19	17	14
Operating income (loss)	(25)	(42)	(53)	(48)	(45)	(6)
Interest income	0	0	1	3	2	0
Interest expense	0	0	—	—	—	—
Other income (expense)	0	1	0	—	—	—
Income tax expense (benefit)	—	—	—	—	0	0
Net income (loss)	(30)	(45)	(57)	(47)	(43)	(8)
Earnings per share, basic‡ USD per share	(12.20)	(10.00)	12.20	(8.96)	(6.88)	(0.58)
Earnings per share, diluted‡ USD per share	(12.20)	(10.00)	12.20	(8.96)	(6.88)	(0.58)
Weighted average shares, basic‡ millions of shares	2	5	5	5	6	13
Weighted average shares, diluted‡ millions of shares	2	5	5	5	6	13

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (September 2023); filings made before it reported them unadjusted.

Fiscal years (CRIS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	130	40	20	27	20	5
Short-term investments	39	—	—	—	—	—
Marketable securities	39	76	66	30	0	—
Accounts receivable	3	3	3	3	3	0
Prepaid and other current assets	1	3	4	2	3	2
Total current assets	173	122	92	61	26	7
Property and equipment, net	1	1	1	0	0	0
Right-of-use asset	7	6	4	3	3	2
Goodwill	9	9	9	9	9	9
Total assets	204	162	109	77	41	20
Accounts payable	4	6	3	3	3	6
Accrued liabilities	4	6	6	9	7	7
Current portion of long-term debt	1	0	—	9	8	0
Total current liabilities	10	13	10	14	19	14
Long-term debt	0	—	—	—	—	—
Lease liability, non-current	5	4	3	1	2	0
Total liabilities	74	72	62	58	47	15
Accumulated deficit	(1,047)	(1,092)	(1,149)	(1,196)	(1,240)	(1,247)
Total stockholders' equity	131	91	47	20	(6)	5
Total liabilities and equity	204	162	109	77	41	20
Common shares outstanding (cover page)‡ millions of shares	5	5	5	6	8	40

‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (September 2023); filings made before it reported them unadjusted.

Fiscal years (CRIS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(30)	(45)	(57)	(47)	(43)	(8)
Stock-based compensation	3	5	7	6	6	4
Net cash from operating activities	(26)	(38)	(54)	(38)	(40)	(27)
Purchases of property and equipment	1	0	0	0	—	—
Net cash from investing activities	(49)	(48)	33	38	29	3
Proceeds from issuing common stock	159	0	6	14	12	15
Net cash from financing activities	189	(4)	1	8	3	10
Net change in cash	114	(90)	(20)	7	(7)	(15)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Curis	5.1	0	(9.6)*	2.1M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Kala Bio	0.2	not reported	(1.5)*	19.3M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Lexaria Bioscience	3.5	0	(1.6)*	24.8M	2.2 quarters	Q3 FY26 10-QMay 31, 2026
Pulmatrix	2.2	not reported	(1.1)*	3.7M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Dyadic International	1.4	1	(1.8)*	36.4M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Scynexis	10	0.2	(15)*	9.9M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
Aytu Biopharma	26	16*	4.4*	10.9M	—	Q4 FY26 10-KJun 30, 2026
Palatin Technologies	7.5	0.3*	(2.7)*	1.8M	2.8 quarters	Q4 FY26 10-KJun 30, 2026
Tenax Therapeutics	118	0*	(14)*	37.4M	8.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.